Oxid Med Cell Longev:褪黑激素可改善机体的氧化应激增加植入物周围的骨量

2019-05-25 不详 网络

植入物周围的骨量减少是植入失败的主要原因,特别是在绝经后骨质疏松症患者中。在骨质疏松症中,氧化应激很大程度上促成了异常的骨重建。由松果体合成的褪黑激素促进成骨细胞分化和骨形成,并且已经有效地用于对抗氧化应激。因此,我们确定褪黑激素是否可以抑制氧化应激,促进骨质疏松症中的成骨和改善植入物周围的骨量。在这项研究中,我们观察到接受50 mg/kg体重的褪黑激素明显增加了卵巢切除(OVX)大鼠的植入物周围

植入物周围的骨量减少是植入失败的主要原因,特别是在绝经后骨质疏松症患者中。在骨质疏松症中,氧化应激很大程度上促成了异常的骨重建。由松果体合成的褪黑激素促进成骨细胞分化和骨形成,并且已经有效地用于对抗氧化应激。因此,我们确定褪黑激素是否可以抑制氧化应激,促进骨质疏松症中的成骨和改善植入物周围的骨量。

在这项研究中,我们观察到接受50 mg/kg体重的褪黑激素明显增加了卵巢切除(OVX)大鼠的植入物周围骨量以及种植体固定强度。同时,与对照组相比,它降低了氧化应激标记物(NAPDH氧化酶2和细胞色素c)的表达,并提高了植入物周围骨(碱性磷酸酶,骨钙素和osterix)形成标志物的表达水平。此外,褪黑激素降低过氧化氢-(H2O2-)诱导的氧化应激并恢复MC3T3-E1细胞的成骨潜力。机制上,与H2O2组相比,褪黑激素明显增加线粒体sirtuin 3(SIRT3)表达并降低乙酰化超氧化物歧化酶2(AC-SOD2)/SOD2的比例。SIRT3抑制作用抵消了褪黑激素对氧化应激和骨形成的保护作用。

总之,结果显示褪黑激素通过SIRT3/SOD2信号通路改善线粒体中的氧化应激,从而促进成骨,改善植入物周围的骨质,并增加初始稳定性。因此,褪黑激素可能是降低植入失败率和延长全关节置换术后假体寿命的合适候选者。

原始出处:

Zhou W, Liu Y, et al., Melatonin Increases Bone Mass around the Prostheses of OVX Rats by Ameliorating Mitochondrial Oxidative Stress via the SIRT3/SOD2 Signaling Pathway. Oxid Med Cell Longev. 2019 Apr 11;2019:4019619. doi: 10.1155/2019/4019619. eCollection 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
    2019-11-05 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
    2019-08-02 clmlylxy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]
    2019-05-27 jiyangfei
  9. [GetPortalCommentsPageByObjectIdResponse(id=1961563, encodeId=e0851961563a6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 05 18:50:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871280, encodeId=1be918e128010, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Aug 16 15:50:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928939, encodeId=f0d91928939e3, content=<a href='/topic/show?id=d77590453d2' target=_blank style='color:#2F92EE;'>#褪黑激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90453, encryptionId=d77590453d2, topicName=褪黑激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sat Apr 18 09:50:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667184, encodeId=8b67166e1849c, content=<a href='/topic/show?id=8863101899aa' target=_blank style='color:#2F92EE;'>#骨量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101899, encryptionId=8863101899aa, topicName=骨量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f026117353, createdName=clmlylxy, createdTime=Fri Aug 02 11:50:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764257, encodeId=64a31e642575d, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Fri Apr 10 10:50:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445284, encodeId=70fb1445284e1, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490912, encodeId=157f1490912cc, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520590, encodeId=281f1520590f1, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609789, encodeId=f4e11609e893d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 27 10:50:00 CST 2019, time=2019-05-27, status=1, ipAttribution=)]